Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 09/24 08:01:57 pm
76.395 EUR   -0.16%
09/21BAYER : collaborates with One Acre Fund to support smallholders in A..
AQ
09/20BAYER : Compugen earns $7.8m payment from Bayer
AQ
09/20BAYER : Levels Sights On Weedkiller Verdict
DJ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
73.3(c) 74.03(c) 75.82(c) 76.52(c) 76.15 Last
3 141 638 3 218 078 5 082 173 8 610 344 2 855 807 Volume
+0.55% +1.00% +2.42% +0.92% -0.48% Change
More quotes
Financials (EUR)
Sales 2018 39 117 M
EBIT 2018 7 261 M
Net income 2018 4 971 M
Debt 2018 39 658 M
Yield 2018 3,70%
Sales 2019 47 216 M
EBIT 2019 9 625 M
Net income 2019 5 469 M
Debt 2019 36 168 M
Yield 2019 3,99%
P/E ratio 2018 15,10
P/E ratio 2019 14,12
EV / Sales2018 2,84x
EV / Sales2019 2,28x
Capitalization 71 359 M
More Financials
Company
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials.It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro.The Pharmaceuticals segment engages in... 
Sector
Pharmaceuticals
Calendar
11/13Earnings Release
More about the company
Surperformance© ratings of Bayer
Trading Rating : Investor Rating :
More Ratings
Latest news on BAYER
12:30pBAYER : Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Co..
AQ
09/22BAYER : Receives Positive CHMP Opinion for Its Hemophilia a Treatment BAY94-9027
AQ
09/22BAYER : Jivi Approved in Japan for Hemophilia a
AQ
09/21BAYER : collaborates with One Acre Fund to support smallholders in Africa with a..
AQ
09/20BAYER : "Fungicidal Compositions And Methods" in Patent Application Approval Pro..
AQ
09/20MONSANTO : Patent Issued for Plants And Seeds Of Hybrid Corn Variety CH624975 (U..
AQ
09/20BAYER : Compugen earns $7.8m payment from Bayer
AQ
09/20MONSANTO : Patent Application Titled "Containerized Liquid Formulations" Publish..
AQ
09/20MONSANTO : Patent Issued for Plants And Seeds Of Hybrid Corn Variety CH895408 (U..
AQ
09/20MONSANTO : Patent Application Titled "Cotton Variety 16r251nrb2xf" Published Onl..
AQ
More news
Sector news : Pharmaceuticals - NEC
08:30aASTRAZENECA : Mixed Results from Farxiga Trial
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
03:05aAs China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on BAYER 
BAYER - 09/17
A good timing to anticipate a change in the trend
BUY
BAYER - 07/11
Still trending down
SELL
More Strategies
Latest Tweets
01:09pStocks to watch: Randgold, Acacia, Tui, Smiths, Comcast, Bayer  
01:03pStocks to watch: Randgold, Acacia, Tui, Smiths, Comcast, Bayer  
01:02pStocks to watch: Randgold, Acacia, Tui, Smiths, Comcast, Bayer
6
12:03pHigh Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin  
11:38aMonsanto India appoints Cherukuri Ravishankar as new MD  
More tweets
Qtime:317
News from SeekingAlpha
09/21Feds looking into free services from drug makers - WSJ 
09/21Bayer's Jivi OK'd in Japan for hemophilia A 
09/20Compugen receives milestone payment in cancer immunotherapy collaboration wit.. 
09/19Bayer steps up legal fight over weedkiller, asks court to toss $289M jury awa.. 
09/18AbbVie used kickbacks to boost Humira sales - CA insurance commissioner 
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 102 €
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-25.23%83 828
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092